Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

Shares of Enliven Therapeutics (ELVN) climbed on Thursday after the cancer drug developer posted initial data from a Phase 1b ...

A study from Washington University School of Medicine in St. Louis suggests a strategy for preventing a chronic, slow-growing type of blood cancer from progressing to an aggressive form of leukemia.

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia ...

When you've been diagnosed with chronic lymphocytic leukemia (CLL), the right support can have a big effect on your quality of life. While it's often a slow-growing type of cancer, there's no cure for ...

The narrative highlights the importance of creating intentional spaces of silence and mindfulness amidst the chaos of chronic ...

Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with allogeneic stem-cell transplantation or favorable-risk CLL treated with chemoimmunotherapy. Treatment ...

Researchers analyzed the diagnostic value of stereotactic brain biopsy in patients with leukemia presenting central ...

Alembic Pharmaceuticals Ltd has obtained tentative approval from the USFDA for its Bosutinib tablets, used to treat specific ...